glp-1 and bipolar Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in disorder: a narrative review of preclinical clinical evidence GLP-1s: Real Stories From People

Clinical trials typically span two to three years, yet real-world prescribing frequently exceeds that timeframe

10.3389/fnins.2018.00073 156 YuH.SunT.HeX.WangZ.ZhaoK.AnJ.et al (2022)

Those who have a BMI of at least 30classified as obese are typically eligible for a GLP-1 prescription

Long-Term Safety Gaps Without human trials, its impossible to rule out risks like abnormal cell growth, cancer promotion, or autoimmune flare-ups

The reason for this extension is due to Patent Term Adjustments (PTA) and Patent Term Extensions (PTE) that the law provides for any delay in patent examination at the United States Patent and Trademark Office (USPTO) and regulatory approval by the U.S